HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.

AbstractBACKGROUND:
The aims of this study were to observe the respiratory syncytial virus (RSV) hospitalization rate and to identify the risk factors for hospitalization for RSV infection among infants in Korea born at <35 weeks of gestational age and who had not previously received palivizumab.
METHODS:
We conducted a study over a 2.5-year period (between April 2007 and September 2009) that included premature infants (<35 weeks of gestational age) who underwent follow-up during 1 year after discharge from the neonatal intensive care unit. Demographic information was collected for each subject at baseline, and the reasons for hospitalization were obtained during the 1-year follow-up period.
RESULTS:
The study population included 1022 subjects who completed follow-up interviews. Eight hundred seventeen infants were included in analysis for RSV hospitalization. Excluded from the study were 167 subjects with chronic lung disease who had received palivizumab prophylaxis and 38 subjects who were not tested for RSV. The overall incidence of RSV hospitalization in the group that did not receive palivizumab was 4.5% (37 of 817 patients). Independent risk factors associated with RSV hospitalization were multiple gestation (P = 0.022) and longer duration of mechanical ventilation in the neonatal intensive care unit (P = 0.039).
CONCLUSION:
This study showed the epidemiology and risk factors of RSV hospitalization in preterm infants in Korea. RSV infection was one of the main causes of hospitalization after discharge from the neonatal intensive care unit in patients born at <35 weeks of gestational age.
AuthorsHye Won Park, Byong Sop Lee, Ai-Rhan Kim, Hye Sun Yoon, Beyong Il Kim, Eun Song Song, Woo Taek Kim, JaeWoo Lim, SeungYeon Kim, Hyun-Seung Jin, ShinYun Byun, Dong Hyun Chee, Ki-Soo Kim
JournalThe Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 31 Issue 8 Pg. e99-104 (Aug 2012) ISSN: 1532-0987 [Electronic] United States
PMID22531234 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab
Topics
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antiviral Agents (therapeutic use)
  • Female
  • Hospitalization
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases (drug therapy, epidemiology)
  • Intensive Care Units, Neonatal (statistics & numerical data)
  • Logistic Models
  • Male
  • Multiple Birth Offspring
  • Palivizumab
  • Prospective Studies
  • Republic of Korea (epidemiology)
  • Respiration, Artificial
  • Respiratory Syncytial Virus Infections (drug therapy, epidemiology)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: